Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Second-line induction therapy with fludarabine, idarubicin, cytarabine,Granulocyte
colony-stimulating factor (G-CSF) and plerixafor, in patients with relapsed or refractory
Acute Myeloblastic Leukemia (AML) aged 65 or younger.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
Cytarabine Fludarabine Fludarabine phosphate Idarubicin JM 3100 Plerixafor